Please login to the form below

Not currently logged in

GSK pledges de-worming tablets to WHO

GlaxoSmithKline (GSK) has signed a pledge to donate 400 million de-worming tablets (albendazole) per year for the next five years to the World Health Organisation (WHO)

GlaxoSmithKline (GSK) today signed a pledge to the World Health Organisation (WHO), promising to donate an additional 400 million tablets of albendazole per year for the next five years to children around the world with intestinal worms.

This donation for 400 million tablets comes after a previous pledge of 600 million tablets of albendazole, which are being used in a Global Programme to Eliminate Lymphatic Filariasis (elephantiasis). This results in GSK donating to the WHO one billion tablets each year for the next five years.

Albendazole is used to treat intestinal worms known as soil-transmitted helminths (STH). These worms are the main cause of disease in school age children in developing countries. They can result in growth stunting, anaemia, malnutrition and poor school performance. 

Around 800 million children in the world are affected by intestinal worms. Children will be treated annually using a single dose of the de-worming medicine.

Shipments have already started and have been received in the African countries Togo and Rwanda. Various other shipments are expected to begin over the next 12 months. In order to meet its commitment, GSK has invested in its factory in South Africa, with its first new production due met month.

12th September 2011


Featured jobs

Subscribe to our email news alerts


Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...